Patents Assigned to Santen Phamaceutical Co., Ltd.
  • INHIBITOR FOR CORNEAL EPITHELIAL CELL DEATH, INHIBITOR CHARACTERIZED BY COMBINING HYALURONIC ACID AND FLAVIN ADENINE DINUCLEOTIDE
    Publication number: 20140228425
    Abstract: A combination of hyaluronic acid or a salt thereof and flavin adenine dinucleotide or a salt thereof can be an inhibitor for corneal epithelial cell death induced by ultraviolet irradiation and/or dryness because it significantly inhibits the decline of the number of living cells in corneal epithelial cells induced by ultraviolet irradiation or dryness.
    Type: Application
    Filed: September 26, 2012
    Publication date: August 14, 2014
    Applicant: Santen Phamaceutical Co., Ltd.
    Inventors: Asuka Sakamoto, Masatsugu Nakamura
  • Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect
    Publication number: 20040242545
    Abstract: According to the present invention, a novel pharmacological effect of a compound having a PI3 kinase inhibitory action was found. Study on a novel pharmacological effect of the compound having a PI3 kinase inhibitory action revealed that the compound has an action of reducing intraocular pressure. Therefore, it is found that the compound having a PI3 kinase inhibitory action is useful as a therapeutic agent for glaucoma.
    Type: Application
    Filed: January 23, 2004
    Publication date: December 2, 2004
    Applicant: Santen Phamaceutical Co., Ltd.
    Inventors: Yoshihisa Otsuka, Atsushi Shimazaki, Takeshi Matsugi, Nobuaki Miyawaki